CompaniesOtherUpdated Oct 14, 2026
Enodia Therapeutics
Private. Enodia Therapeutics is a biotechnology company focused on developing best-in-class small-molecule therapies that enable the degradation of disease-driving proteins at the point of synthesis, before they have a damaging effect.
- Last round
- €20.7M Seed
- Backed by
- Elaia
- Launched
- 2025
- People
- 4
Overview
Updated Oct 14, 2026
Every fact carries a numbered source. Where we can't source something, it says so.
Identity fields from the company record are sourced where a source is recorded; those have no number.
Funding
How much has Enodia Therapeutics raised?
Rounds and backers, each sourced.
Opportunities For accredited investors
Ways to invest in this company through an Alphaneo vehicle, when one exists. This section looks the same on every company page until you have an accredited profile.
Opportunities, terms and data rooms are shown to accredited investors. Creating a profile takes two minutes, and you’re notified first when anything opens.
No live opportunities right now. Accredited investors are notified first when one opens.
Create an accredited profileA vehicle is never smaller than $1,000,000.
People
Who founded and leads Enodia Therapeutics?
Names and titles only, each sourced.
Sources
Every claim on this page traces to one of these. The numbers match the citations above.
- 1
- 2Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules opens in a new tabHeadquarters, People · accessed Oct 14, 2026
- 3News & Events - Enodia Therapeutics opens in a new tabStage, Total raised, Funding, People · accessed Oct 14, 2026
- 4About us - Enodia Therapeutics opens in a new tabPeople · accessed Oct 14, 2026
- 5Enodia therapeutics - a new approach for Targeted protein Degradation opens in a new tabWebsite · accessed Oct 14, 2026